Immunophenotypic and Genetic Features of ALK1-Positive/t(2; 5)-Negative Large Cell Lymphomas
| Cases No. (sex/age) Markers . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . |
|---|---|---|---|---|---|---|---|
| . | (M/53) . | (M/15) . | (M/37) . | (M/44) . | (F/67) . | (M/51) . | (M/60) . |
| ALK1 | + | + | + | + | + | + | +(W) |
| ALK-EC | + | + | + | + | + | + | + |
| RT-PCR | |||||||
| -t(2; 5) | − | NT | NT | − | NT | − | NT |
| -ALK mRNA | + | NT | NT | NT | NT | + | NT |
| EMA | + | + | + | + | + | + | + |
| CD30 | − | − | − | − | − | − | − |
| CD25 | − | +(W) | NT | − | NT | NT | +(W) |
| CD15 | −/+ | + | − | −/+ | − | − | − |
| BNH.9 | − | − | − | − | − | − | − |
| CD45 | + | −/+ | + | − | + | + | + |
| CD20 | − | − | − | − | − | − | − |
| CD79a | − | − | − | − | − | − | − |
| Anti-Ig | IgAκ | IgAκ | IgAλ | − | κ | IgAλ | IgAλ |
| VS38* | + | + | + | + | + | + | + |
| CD1 | − | − | NT | − | NT | NT | − |
| CD2 | − | − | NT | − | NT | − | − |
| CD3 | − | − | − | − | − | − | − |
| CD4 | + | + | NT | + | NT | + | + |
| CD5 | − | − | NT | − | NT | − | − |
| CD8 | − | − | NT | − | NT | − | − |
| CD43 | − | − | − | − | − | − | − |
| CD45RO | − | −/+ | − | − | − | − | − |
| CBF.78 | − | − | − | − | − | − | − |
| CD57 | −/+ | −/+ | −/+ | −/+ | − | − | −/+ |
| CD68 | − | − | − | − | − | − | − |
| CD34 | − | − | − | − | − | − | − |
| EBV† | − | − | − | − | − | − | − |
| Cases No. (sex/age) Markers . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . |
|---|---|---|---|---|---|---|---|
| . | (M/53) . | (M/15) . | (M/37) . | (M/44) . | (F/67) . | (M/51) . | (M/60) . |
| ALK1 | + | + | + | + | + | + | +(W) |
| ALK-EC | + | + | + | + | + | + | + |
| RT-PCR | |||||||
| -t(2; 5) | − | NT | NT | − | NT | − | NT |
| -ALK mRNA | + | NT | NT | NT | NT | + | NT |
| EMA | + | + | + | + | + | + | + |
| CD30 | − | − | − | − | − | − | − |
| CD25 | − | +(W) | NT | − | NT | NT | +(W) |
| CD15 | −/+ | + | − | −/+ | − | − | − |
| BNH.9 | − | − | − | − | − | − | − |
| CD45 | + | −/+ | + | − | + | + | + |
| CD20 | − | − | − | − | − | − | − |
| CD79a | − | − | − | − | − | − | − |
| Anti-Ig | IgAκ | IgAκ | IgAλ | − | κ | IgAλ | IgAλ |
| VS38* | + | + | + | + | + | + | + |
| CD1 | − | − | NT | − | NT | NT | − |
| CD2 | − | − | NT | − | NT | − | − |
| CD3 | − | − | − | − | − | − | − |
| CD4 | + | + | NT | + | NT | + | + |
| CD5 | − | − | NT | − | NT | − | − |
| CD8 | − | − | NT | − | NT | − | − |
| CD43 | − | − | − | − | − | − | − |
| CD45RO | − | −/+ | − | − | − | − | − |
| CBF.78 | − | − | − | − | − | − | − |
| CD57 | −/+ | −/+ | −/+ | −/+ | − | − | −/+ |
| CD68 | − | − | − | − | − | − | − |
| CD34 | − | − | − | − | − | − | − |
| EBV† | − | − | − | − | − | − | − |
Monotypic Ig was demonstrated by immunohistochemistry and in situ hybridization.
Abbreviations: W, weak staining; −/+, heterogeneous staining with <50% of cells positive; NT, not tested.
VS38 antibody detects an endoplasmic reticulum–associated molecule also expressed by some large B-cell lymphomas; CBF.78 detects a novel T-cell–associated antigen expressed by the majority of CD30+ anaplastic large cell lymphomas.12
Analyzed using anti-LMP1 antibody and EBER in situ hybridization.